Platelet-Leukocyte Interactions in Sepsis

脓毒症中血小板与白细胞的相互作用

• 批准号: 10301082
• 负责人: Matthew Thomas Rondina
• 金额: $ 12.12万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-01 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10301082
• 关键词: Agonist; Antigen Presentation; Antigen Presentation Pathway; Antigen-Presenting Cells; Antigens; Apoptosis; Area; Award; Bioinformatics; Biological; Blood Platelets; CD8-Positive T-Lymphocytes; Cardiovascular Diseases; Cell Count; Cell physiology; Cells; Cellular biology; Clinical; Clinical Data; Clinical Investigator; Clinical Research; Communicable Diseases; Critical Care; Data; Data Collection; Discipline; Doctor of Philosophy; Effectiveness; Effector Cell; Event; Fellowship; Funding; Gene Expression; Grant; Hematology; Human; Immune System Diseases; Immunity; Immunology; Immunosuppression; Impairment; Inflammatory; Knowledge; Learning; Leukocytes; Lung; Major Histocompatibility Complex; Malignant Neoplasms; Mediating; Megakaryocytes; Mentors; Mentorship; Methods; Mid-Career Clinical Scientist Award (K24); Midcareer Investigator Award in Patient-Oriented Research; Molecular; Molecular Medicine; Morbidity - disease rate; National Heart, Lung, and Blood Institute; Outcome; Participant; Pathogenicity; Patients; Peptides; Phenotype; Process; Proteins; Proteome; Publishing; RNA; Research; Research Activity; Research Personnel; Research Project Grants; Risk; Role; Sample Size; Sampling; Secondary to; Sentinel; Sepsis; Students; Supervision; Survivors; T-Lymphocyte; TNFSF15 gene; Techniques; Testing; Time; Tissue-Specific Gene Expression; Training; Underrepresented Minority; Universities; Up-Regulation; Utah; Work; adverse outcome; base; biomedical scientist; career; career development; cohort; cytokine; design; gene function; genome editing; improved; innovation; innovative technologies; monocyte; next generation; novel; novel therapeutic intervention; patient oriented research; platelet function; programs; recruit; response; role model; secondary infection; septic; septic patients; skills; tool; transcriptome; transcriptome sequencing

This is a revised NHLBI K24 application for Dr. Matthew Rondina’s Midcareer Investigator Award in Patient- Oriented Research. At the University of Utah, Dr. Rondina is the contact PI for a funded NHLBI R01 and VA Merit Award supporting the longitudinal recruitment of sepsis patients, as well as platelet isolation, clinical data collection, and outcomes analyses. He mentors a large and growing cadre of clinical investigators from diverse disciplines. Dr. Rondina’s overall aims are to 1) improve his skills as a mentor and therefore serve more effectively as a role model for, and mentor to, junior investigators devoted to patient-oriented research; 2) determine how sepsis upregulates antigen presentation by MHCI on platelets, thereby contributing to CD8+ T cell suppression and immune dysfunction; and 3) engage in focused and carefully selected career development activities to increase his knowledge of T cell biology and immunology – improving his ability to mentor clinical trainees in this area. This application describes career development, mentoring, and research activities that would be executed in the next five years under protected time afforded by this NHLBI K24 award. Dr. Rondina’s mentees will learn and apply innovative technologies to study platelets and leukocytes in sepsis patients and appropriate control participants, and to determine if platelet/leukocyte changes in sepsis are associated with clinical outcomes. This patient-oriented research project will serve as a platform for Dr. Rondina to expand his mentorship for trainees to engage in patient-oriented research on their path towards successful, independent careers. Dr. Rondina will engage in career development activities during this project period, including 1) improving his mentoring skills for junior clinician investigators, including underrepresented minorities, and 2) expanding his knowledge of immunology and CD8+ T cell biology. These activities will expand Dr. Rondina’s mentoring capacity, effectiveness, and reach over the five-year award period. He has ample access to mentees through his work with the VPCAT and Molecular Medicine Programs, the Utah StARR Program, and the Utah CTSA KL2 and TL1 Programs. In addition, Dr. Rondina will interface with clinical fellows in subspecialty fellowships pertinent to the research proposed (e.g. Pulmonary and Critical Care, Hematology, Infectious Disease), with students in the University of Utah MD and MD/PhD Programs, and with junior investigators from traditionally underrepresented backgrounds. The K24 award will enable Dr. Rondina to significantly expand his active mentoring roles and patient-oriented research and will lead to the training of the next-generation of biomedical scientists.

这是Matthew Rondina博士的中级护理调查员奖的NHLBI K24申请。 定向研究。在犹他大学，Rondina博士是资助NHLBI R01和VA的PI 支持败血症患者纵向招募以及血小板隔离，临床数据的绩效奖 收集和结果分析。他指导了来自潜水员的大量临床研究人员 学科。 Rondina博士的总体目标是1）提高他的精神技能，因此为更多服务提供服务 有效地作为致力于患者研究的初级研究人员的榜样，并成为心理的榜样； 2） 确定败血症如何上调MHCI在血小板上的抗原表现，从而有助于CD8+ T 细胞抑制和免疫功能障碍； 3）参与重点和精心选择的职业发展 提高他对T细胞生物学和免疫学知识的活动 - 提高了他的精神临床能力 该地区的学员。该应用程序描述了职业发展，心理和研究活动 该NHLBI K24奖的保护时间将在未来五年内执行。 Rondina博士 Menees将学习和应用创新技术来研究败血症患者的血小板和白细胞 适当的控制参与者，并确定败血症中的血小板/白细胞变化是否与 临床结果。这个面向患者的研究项目将成为Rondina博士扩展的平台 他为受训者提供的精神制，从事以患者为导向的研究，从 独立职业。 Rondina博士将在这个项目期间从事职业发展活动， 包括1）提高他为初级临床研究人员（包括代表性不足的少数民族）提高他的心理技能， 2）扩大他对免疫学和CD8+ T细胞生物学的了解。这些活动将扩大博士。 Rondina的心理能力，有效性以及五年奖励期。他有足够的访问权限 通过与VPCAT和Molecular Medicine计划的工作，犹他州Starr计划， 以及犹他州CTSA KL2和TL1程序。此外，Rondina博士将与临床研究员接触 与拟议的研究相关的专业研究金（例如，肺和重症监护，血液学， 传染病），犹他大学和医学博士/博士学位课程的学生以及初中 传统上代表性不足的背景的调查人员。 K24奖将使Rondina博士能够 显着扩大他积极的心理角色和面向患者的研究，并将导致培训 生物医学科学家的下一代。